Characterizing biological products and assessing comparability following manufacturing changes

被引:270
作者
Chirino, AJ
Mire-Sluis, A
机构
[1] Xencor Inc, Monrovia, CA 91016 USA
[2] Ctr Drug Evaluat & Res, Off Pharmaceut Sci, Rockville, MD 20852 USA
关键词
D O I
10.1038/nbt1030
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Changes in production methods of a biological product may necessitate an assessment of comparability to ensure that these manufacturing changes have not affected the safety, identity, purity, or efficacy of the product. Depending on the nature of the protein or the change, this assessment consists of a hierarchy of sequential tests in analytical testing, preclinical animal studies and clinical studies. Differences in analytical test results between pre- and post-change products may require functional testing to establish the biological or clinical significance of the observed difference. An underlying principle of comparability is that under certain conditions, protein products may be considered comparable on the basis of analytical testing results alone. However, the ability to compare biological materials is solely dependent on the tests used, since no single analytical method is able to compare every aspect of protein structure or function. The advantages and disadvantages of any given method depends on the protein property being characterized.
引用
收藏
页码:1383 / 1391
页数:9
相关论文
共 92 条
  • [81] Detection and characterization of antibodies to PEG-IFN-α2b using surface plasmon resonance
    Takacs, MA
    Jacobs, SJ
    Bordens, RM
    Swanson, SJ
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (07) : 781 - 789
  • [82] VANDENHA.CJ, 1970, J BIOL CHEM, V245, P4397
  • [83] A case study and use of sedimentation equilibrium analytical ultracentrifugation as a tool for biopharmaceutical development
    Varley, PG
    Brown, AJ
    Dawkes, HC
    Burns, NR
    [J]. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 1997, 25 (5-6): : 437 - 443
  • [84] Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals
    Wadhwa, M
    Bird, C
    Dilger, P
    Gaines-Das, R
    Thorpe, R
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 278 (1-2) : 1 - 17
  • [85] Wadhwa M, 1999, CLIN CANCER RES, V5, P1353
  • [86] STRUCTURE DETERMINATION OF THE INTACT MAJOR SIALYLATED OLIGOSACCHARIDE CHAINS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN EXPRESSED IN CHINESE-HAMSTER OVARY CELLS
    WATSON, E
    BHIDE, A
    VANHALBEEK, H
    [J]. GLYCOBIOLOGY, 1994, 4 (02) : 227 - 237
  • [87] Immunogenicity of biopharmaceuticals in laboratory animals
    Wierda, D
    Smith, HW
    Zwickl, CM
    [J]. TOXICOLOGY, 2001, 158 (1-2) : 71 - 74
  • [88] Wright A, 1998, J IMMUNOL, V160, P3393
  • [89] In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure
    Wright, A
    Sato, Y
    Okada, T
    Chang, KH
    Endo, T
    Morrison, SL
    [J]. GLYCOBIOLOGY, 2000, 10 (12) : 1347 - 1355
  • [90] Effect of glycosylation on antibody function: Implications for genetic engineering
    Wright, A
    Morrison, SL
    [J]. TRENDS IN BIOTECHNOLOGY, 1997, 15 (01) : 26 - 32